| Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798) |
|---|
| 08/01/2001 | CN1069043C Medicine for treating lithiasis |
| 08/01/2001 | CN1069041C Traditional chinese medicine prepn. for eradicating helicobacter phlori |
| 07/31/2001 | US6268507 Hydantoin derivatives |
| 07/31/2001 | US6268502 Process of synthesis of 5-methoxy- 2-[(4-methoxy-3,5-dimethy-2-pyridyl)methyl]sulfiny-1h-benzimidazole |
| 07/31/2001 | US6268398 Aromatic guanidine derivatives |
| 07/31/2001 | US6268391 Benzylidene-1,3-dihydro-indol-2-one derivatives a receptor tyrosine kinase inhibitors, particularly of Raf kinases |
| 07/31/2001 | US6268385 Dry blend pharmaceutical formulations |
| 07/31/2001 | US6268379 Substituted aryl hydroxamic acids as metalloproteinase inhibitors |
| 07/31/2001 | US6268365 Src family SH2 domain inhibitors |
| 07/31/2001 | US6268346 Having high biological activity of the same type as the known natural compound bpc, but with shorter amino acid chains. |
| 07/31/2001 | US6268342 Method of inhibiting fibrosis with a somatostatin agonist |
| 07/31/2001 | US6268207 Resolution of enantiomers from a mixture of (1r,2s)/(1s,2s)-1-amino-2-vinylcyclopropyl carboxylic acid methyl ester comprising the step of treating said mixture with an esterase to obtain the corresponding (1r,2s) enantiomer |
| 07/31/2001 | US6268182 Enzymatically degrading starch in combination with glycosyltransferase to act on starch having at least one phosphate group per molecule; phosphorylated saccharide reacts with minerals and prevents insolubization of minerals |
| 07/31/2001 | CA2241445C Non-aqueous colonic purgative formulations |
| 07/31/2001 | CA2118119C Methods for treating interleukin-1 and tumor necrosis factor mediated diseases |
| 07/31/2001 | CA2068763C Use of dibutyl adipate and isopropyl myristate in topical and transdermal products |
| 07/26/2001 | WO2001053540A1 Antisense modulation of pepck-cytosolic expression |
| 07/26/2001 | WO2001053468A2 Lipid metabolism enzymes and polynucleotides encoding them |
| 07/26/2001 | WO2001053462A1 Liver tissue source |
| 07/26/2001 | WO2001053348A2 Human polypeptides related to the vanilloid and trp families of cation channel proteins and nucleic acids encoding them |
| 07/26/2001 | WO2001053344A2 Chondromodulin-i related peptide |
| 07/26/2001 | WO2001053343A1 Human polynucleotides, polypeptides, and antibodies |
| 07/26/2001 | WO2001053311A1 Antisense modulation of peroxisome proliferator-activated receptor gamma expression |
| 07/26/2001 | WO2001053310A1 Antisense modulation of caspase 3 expression |
| 07/26/2001 | WO2001053295A1 Bicyclic heteroaryl compounds as inhibitors of the interaction between the integrin alpha4beta1 receptor and vcam-1 and/or fibronectin |
| 07/26/2001 | WO2001053278A1 2-thio-4h-3,1-benzoxazin-4-one derivatives for use as enzyme inhibitors |
| 07/26/2001 | WO2001053263A1 Corticotropin releasing factor antagonists |
| 07/26/2001 | WO2001053261A1 Substituted glutarimides and use thereof il-12 production inhibitors |
| 07/26/2001 | WO2001053256A1 Substituted benzoylguanidines, method for their production, their use as a medicament or diagnostic agent and a medicament containing the same |
| 07/26/2001 | WO2001053254A1 Calcilytic compounds |
| 07/26/2001 | WO2001052903A1 Method for nucleic acid transfection of cells |
| 07/26/2001 | WO2001052880A1 Cyclic peptides as potent and selective melanocortin-4 receptor antagonists |
| 07/26/2001 | WO2001052858A1 Tetracycline compounds for treatment of cryptosporidium parvum related disorders |
| 07/26/2001 | WO2001052845A1 Gyrase inhibitors and uses thereof |
| 07/26/2001 | WO2001052834A1 Remedies for hepatitis containing alanine and glycine |
| 07/26/2001 | WO2001052829A2 Statin-type bone growth stimulators |
| 07/26/2001 | WO2001052824A2 Use of particular compounds for prophylaxis and treatment of hepatitis c |
| 07/26/2001 | WO2001052816A2 Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same |
| 07/26/2001 | WO2001052815A1 Multi-step drug dosage forms |
| 07/26/2001 | WO2001052796A2 Methods of using a beverage composition for treating dental erosion |
| 07/26/2001 | WO2001052667A2 Pet food composition for treating helicobacter species in pets |
| 07/26/2001 | WO2001052664A1 Immune modulation with death receptor-induced apoptosis |
| 07/26/2001 | US20010009921 Pyrrolidinyl and pyrrolinyl ethylamine compounds as kappa agonists |
| 07/26/2001 | US20010009917 Reducing associated adverse effects; 5-lipoxygenase inhibitor, useful in treatment of conditions related to elevated leukotriene levels |
| 07/26/2001 | US20010009670 Parenterally administering large liposomes comprised of phospholipids substantially free of sterol, where the liposomes pick-up cholesterol |
| 07/26/2001 | DE10002509A1 New substituted glutarimide derivatives are IL-12 antagonists, are useful as immunomodulators and for the treatment of angiopathy, hematological or oncological disorders |
| 07/26/2001 | DE10001729A1 Treatment or prevention of hepatitis C infection by administration of certain bicyclic compounds, e.g. 2-methyl-1,4-naphthoquinone |
| 07/26/2001 | CA2398695A1 Chondromodulin-i related peptide |
| 07/26/2001 | CA2398061A1 Substituted glutarimides and their use as inhibitors of il-12 production |
| 07/26/2001 | CA2397946A1 Lipid metabolism enzymes |
| 07/26/2001 | CA2397927A1 Liver tissue source |
| 07/26/2001 | CA2397863A1 Tetracycline compounds for treatment of cryptosporidium parvum related disorders |
| 07/26/2001 | CA2397802A1 Calcilytic compounds |
| 07/26/2001 | CA2397686A1 Gyrase inhibitors and uses thereof |
| 07/26/2001 | CA2397659A1 Statin-type bone growth stimulators |
| 07/26/2001 | CA2397633A1 Corticotropin releasing factor antagonists |
| 07/26/2001 | CA2397617A1 Novel human nucleic acid molecules and polypeptides encoding cation channels |
| 07/26/2001 | CA2397531A1 Substituted benzoylguanidines, method for their production, their use as a medicament or diagnostic agent and a medicament containing the same |
| 07/26/2001 | CA2397492A1 Method for nucleic acid transfection of cells |
| 07/26/2001 | CA2396979A1 Immune modulation with death receptor-induced apoptosis |
| 07/26/2001 | CA2396307A1 Cyclic peptides as potent and selective melanocortin-4 receptor antagonists |
| 07/26/2001 | CA2395974A1 Multi-step drug dosage forms |
| 07/26/2001 | CA2395054A1 Human polynucleotides, polypeptides, and antibodies |
| 07/26/2001 | CA2393694A1 Use of particular compounds for prophylaxis and treatment of hepatitis c |
| 07/26/2001 | CA2332214A1 Compositions and methods for treating osteoporosis and lowering cholesterol |
| 07/26/2001 | CA2332208A1 Pharmacophore models for, methods of screening for, and identification of the cytochrome p-450 inhibitory potency of neurokinin-1 receptor antagonists |
| 07/25/2001 | EP1118663A1 Nucleic acids encoding chemotaxis inhibitory polypeptides |
| 07/25/2001 | EP1118615A1 Novel salts of pyridopyrazine compound and crystals thereof |
| 07/25/2001 | EP1117795A2 Tgf-beta superfamily mutant members, including morphogenic proteins |
| 07/25/2001 | EP1117785A1 Human kinesin-like motor protein |
| 07/25/2001 | EP1117764A1 Primate embryonic stem cells with compatible histocompatibility genes |
| 07/25/2001 | EP1117695A1 Biocompatible polymers, preparation method and compositions containing same |
| 07/25/2001 | EP1117680A2 Ncam binding compounds |
| 07/25/2001 | EP1117658A1 1,3-benzodiazepines with integrin inhibitory activity for use in the treatment of inflammatory disorders |
| 07/25/2001 | EP1117657A1 Phenylalanine derivatives as alpha 4 integrin inhibitors |
| 07/25/2001 | EP1117653A1 Chemical compounds |
| 07/25/2001 | EP1117648A1 Tetrahydroquinoline derivatives having selective activity for retinoid x receptors |
| 07/25/2001 | EP1117640A1 Heterocyclic 2-substituted ketoamides useful for treating hair loss in mammals |
| 07/25/2001 | EP1117633A1 Diaminocyclobutene-3,4-dione derivatives, their preparation and use |
| 07/25/2001 | EP1117628A1 2, 4-pentadienoic acid derivatives having selective activity for retinoid x (rxr) receptors |
| 07/25/2001 | EP1117443A1 Peptide-based carrier devices for stellate cells |
| 07/25/2001 | EP1117431A1 Control of acidosis |
| 07/25/2001 | EP1117398A2 A method for treating inflammatory diseases by administering a thrombin inhibitor |
| 07/25/2001 | EP1117396A1 A method to increase the excretion of non-sterol endogenous hydrophobic substances by increasing excretion of fat via the faeces |
| 07/25/2001 | EP1117388A1 Antioxidant gel for gingival conditions |
| 07/25/2001 | EP1117296A1 Combination of bisphosphonate and tetracycline |
| 07/25/2001 | EP1104653A9 Composition for animals containing a methyl salicylate |
| 07/25/2001 | EP0772610B9 Dihydrobenzofuranes |
| 07/25/2001 | EP0677049B1 Quinazoline derivatives |
| 07/25/2001 | EP0585444B1 Hepatoma treatment with somatostatin analogs |
| 07/25/2001 | CN1305496A Cyclic somatostatin analogs |
| 07/25/2001 | CN1305487A Benzo (b) thiepine-1, 1-dioxide derivatives, method for production thereof, medicaments containing these compounds and their use |
| 07/25/2001 | CN1305480A Pyrolo [2,3-d] pyrimidine compounds |
| 07/25/2001 | CN1305479A Pyrrolo [2,3-d] pyrmidine compounds |
| 07/25/2001 | CN1305478A Pyrazolopyrimidinone cGMP PDE 5 inhibitors for treatment of sexual dysfunction |
| 07/25/2001 | CN1305477A Azablicyclic 5-HT, receptor ligands |
| 07/25/2001 | CN1305473A N,N-disubstituded amide for inhibit binding of integrins to their receptors protein |
| 07/25/2001 | CN1305471A Dihydropyrimidines |
| 07/25/2001 | CN1305469A Benzothiepine-1, 1-dioxide derivatives, method for producing them, medicaments containing these compounds and their use |
| 07/25/2001 | CN1305465A Aryl alkanoylpyridazines |